This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors

Eli Lilly's oral GLP-1 candidate, orforglipron, reported disappointing Phase 3 weight management data, achieving an average 12.4% weight reduction, which fell short of investor and analyst expectations. This setback for Lilly, a major player in the GLP-1 market, creates a significant opportunity for competitors in the burgeoning oral GLP-1 space, projected to reach $20 billion by 2030. Notably, Novo Nordisk, which already has an approved oral GLP-1 (Rybelsus) and is advancing its own oral weight-loss candidate (amycretin) in Phase 3, stands to benefit from this shift in the competitive landscape.

Analysis

Eli Lilly's (LLY) recent Phase 3 trial data for its oral GLP-1 candidate, orforglipron, has significantly altered the competitive landscape for the burgeoning oral weight-loss market, which is projected to reach $20 billion by 2030. The trial's reported 12.4% average weight reduction in non-diabetic patients fell short of analyst expectations of around 14.4% and is notably less effective than injectable counterparts like Lilly's own Zepbound (20.2%). This clinical setback, which prompted a decline in LLY's share price, creates a strategic opening for its primary competitor, Novo Nordisk (NVO). Novo Nordisk, whose shares rose on the news, is already advancing its own oral weight-loss candidate, amycretin, into Phase 3 studies and has existing commercial experience in the oral GLP-1 space with its diabetes drug, Rybelsus. The disappointing results for orforglipron also potentially increase the relevance of smaller biotechs, such as Viking Therapeutics and Structure Therapeutics, that are developing their own oral GLP-1 candidates.

Key Decisions for Investors

• Re-evaluate exposure across the GLP-1 space, as Eli Lilly's clinical setback for orforglipron materially improves the competitive positioning of Novo Nordisk and other developers of oral weight-loss drugs.
• For investors in Eli Lilly, the key consideration is whether the strength of its existing injectable portfolio and diversified pipeline can offset the diminished expectations for its oral GLP-1 franchise.
• Novo Nordisk's stock may see further upside pending positive Phase 3 data from its oral candidate, amycretin, making this a key catalyst to monitor for those looking to capitalize on the market shift.
• Consider that the valuations of smaller biotechs like Viking Therapeutics and Structure Therapeutics are now more sensitive to their own clinical trial outcomes in a less certain competitive field.